Purchase this article with an account.
Jihwan Lee, Seo Hee Kim, SungChul Lee, Christopher Seungkyu Lee; Choroidal morphology and chorioretinal atrophy in myopic choroidal neovascularization with anti-vascular endothelial growth factor therapy. Invest. Ophthalmol. Vis. Sci. 2016;57(12):4650.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The present study investigated factors associated with chorioretinal atrophy (CRA) progression in myopic choroidal neovascularization (CNV) after anti-vascular endothelial growth factor (VEGF) therapy.
Fifty eyes of 50 treatment-naïve patients with myopic CNV who underwent anti-VEGF monotherapy with at least 2 years of follow-up data were included. The cumulative incidence of CRA progression was assessed using a Kaplan-Meier analysis. Demographic and clinical characteristics including macular choroidal thickness in various areas were compared between patients with and without CRA progression.
The mean age was 52.34 years. A mean of 4.84 anti-VEGF injections were performed over the mean follow-up duration of 44.6 months. Eventually, 15 eyes (30%) developed CRA progression. The estimated incidence of CRA progression was 10% at 1 year, 19.1% at 2 years, 23.6% at 3 and 4 years, and 35.4% at 5 years. CRA progression was associated with a subfoveal CNV location (P = 0.029) and thinner subfoveal choroid in relation to the inferior choroid at 3 mm (P = 0.008). Visual improvement was only significant in eyes without CRA progression at 1 year, 2 years, and at the final visit.
CRA progression was associated with a poor long-term prognosis. Relative thinning of the subfoveal choroid with respect to the inferior choroid and subfoveal CNV location may predispose eyes with myopic CNV to develop CRA progression after anti-VEGF therapy.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.
This PDF is available to Subscribers Only